Mr. Aaron Benson reports

ARCH BIOPARTNERS ARRANGES NON-BROKERED PRIVATE PLACEMENT

Arch Biopartners Inc. has arranged a non-brokered private placement offering of one million common shares priced at 60 cents per common share for gross proceeds of $600,000.

The proceeds of the offering will be used by Arch as general working capital and for certain operating expenses that are not covered by the company's human trial financing grants. The offering is expected to close on April 2, 2026, and is subject to certain conditions, including, but not limited to, the receipt of applicable regulatory approvals, including conditional and final approval from the TSX Venture Exchange, as well as the satisfaction of customary closing conditions.

All common shares issued in connection with the offering will be subject to a hold period of four months and one day from the closing date. There are no finders' fees to be paid in connection with the offering.

There is no material fact or material change about the company that has not been generally disclosed.

About Arch Biopartners Inc.

Arch Biopartners is a therapeutic biotechnology company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.

Arch's development pipeline includes:

• LSALT peptide: in a phase II trial targeting cardiac-surgery-associated AKI;
• Cilastatin: a repurposed drug in a phase II trial targeting toxin-induced AKI;
• CKD platform: next-generation therapeutics targeting chronic kidney disease.

These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people around the world. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development.

The company has 66,933,289 common shares outstanding.